188 related articles for article (PubMed ID: 30297863)
1. Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease.
Ebrahimi D; Richards CM; Carpenter MA; Wang J; Ikeda T; Becker JT; Cheng AZ; McCann JL; Shaban NM; Salamango DJ; Starrett GJ; Lingappa JR; Yong J; Brown WL; Harris RS
Nat Commun; 2018 Oct; 9(1):4137. PubMed ID: 30297863
[TBL] [Abstract][Full Text] [Related]
2. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.
Wang X; Abudu A; Son S; Dang Y; Venta PJ; Zheng YH
J Virol; 2011 Apr; 85(7):3142-52. PubMed ID: 21270145
[TBL] [Abstract][Full Text] [Related]
3. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.
Ooms M; Letko M; Binka M; Simon V
PLoS One; 2013; 8(2):e57744. PubMed ID: 23469063
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Vif adaptation to human APOBEC3H haplotypes.
Ooms M; Brayton B; Letko M; Maio SM; Pilcher CD; Hecht FM; Barbour JD; Simon V
Cell Host Microbe; 2013 Oct; 14(4):411-21. PubMed ID: 24139399
[TBL] [Abstract][Full Text] [Related]
5. Natural Polymorphisms and Oligomerization of Human APOBEC3H Contribute to Single-stranded DNA Scanning Ability.
Feng Y; Love RP; Ara A; Baig TT; Adolph MB; Chelico L
J Biol Chem; 2015 Nov; 290(45):27188-27203. PubMed ID: 26396192
[TBL] [Abstract][Full Text] [Related]
6. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.
Zhen A; Wang T; Zhao K; Xiong Y; Yu XF
J Virol; 2010 Feb; 84(4):1902-11. PubMed ID: 19939923
[TBL] [Abstract][Full Text] [Related]
7. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.
Ooms M; Majdak S; Seibert CW; Harari A; Simon V
J Virol; 2010 Aug; 84(16):7961-9. PubMed ID: 20519396
[TBL] [Abstract][Full Text] [Related]
8. Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities.
Mitra M; Singer D; Mano Y; Hritz J; Nam G; Gorelick RJ; Byeon IJ; Gronenborn AM; Iwatani Y; Levin JG
Retrovirology; 2015 Jan; 12():3. PubMed ID: 25614027
[TBL] [Abstract][Full Text] [Related]
9. The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H.
Wang J; Becker JT; Shi K; Lauer KV; Salamango DJ; Aihara H; Shaban NM; Harris RS
J Mol Biol; 2019 Dec; 431(24):5019-5031. PubMed ID: 31628948
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H.
Harari A; Ooms M; Mulder LC; Simon V
J Virol; 2009 Jan; 83(1):295-303. PubMed ID: 18945781
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
12. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
Ooms M; Letko M; Simon V
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
[TBL] [Abstract][Full Text] [Related]
13. APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection.
Gourraud PA; Karaouni A; Woo JM; Schmidt T; Oksenberg JR; Hecht FM; Liegler TJ; Barbour JD
Hum Immunol; 2011 Mar; 72(3):207-12. PubMed ID: 21167246
[TBL] [Abstract][Full Text] [Related]
14. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.
Refsland EW; Hultquist JF; Luengas EM; Ikeda T; Shaban NM; Law EK; Brown WL; Reilly C; Emerman M; Harris RS
PLoS Genet; 2014 Nov; 10(11):e1004761. PubMed ID: 25411794
[TBL] [Abstract][Full Text] [Related]
15. Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif.
Zhao K; Du J; Rui Y; Zheng W; Kang J; Hou J; Wang K; Zhang W; Simon VA; Yu XF
Cell Cycle; 2015; 14(6):838-47. PubMed ID: 25590520
[TBL] [Abstract][Full Text] [Related]
16. Biochemical Characterization of APOBEC3H Variants: Implications for Their HIV-1 Restriction Activity and mC Modification.
Gu J; Chen Q; Xiao X; Ito F; Wolfe A; Chen XS
J Mol Biol; 2016 Nov; 428(23):4626-4638. PubMed ID: 27534815
[TBL] [Abstract][Full Text] [Related]
17. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities.
Zhen A; Du J; Zhou X; Xiong Y; Yu XF
PLoS One; 2012; 7(7):e38771. PubMed ID: 22859935
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.
Nakano Y; Misawa N; Juarez-Fernandez G; Moriwaki M; Nakaoka S; Funo T; Yamada E; Soper A; Yoshikawa R; Ebrahimi D; Tachiki Y; Iwami S; Harris RS; Koyanagi Y; Sato K
PLoS Pathog; 2017 May; 13(5):e1006348. PubMed ID: 28475648
[TBL] [Abstract][Full Text] [Related]
19. Human cytidine deaminase APOBEC3H restricts HIV-1 replication.
Dang Y; Siew LM; Wang X; Han Y; Lampen R; Zheng YH
J Biol Chem; 2008 Apr; 283(17):11606-14. PubMed ID: 18299330
[TBL] [Abstract][Full Text] [Related]
20. Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity.
Bohn JA; DaSilva J; Kharytonchyk S; Mercedes M; Vosters J; Telesnitsky A; Hatziioannou T; Smith JL
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
